Yahoo Web Search

  1. This compares to a loss per share of 15 cents a year ago. p> The Zacks Rank #4 (Sell) company's quarterly sales totaled $58.6 million, which beat the Zacks Consensus Estimate by 4.3%. On a year-over-year basis, revenues surged 35.8%.

  2. Globus Medical (GMED) Q2 Earnings In Line, Revenue View Up

    Zacks via Yahoo FinanceAug 02 15:38 PM

    However, Enabling Technologies products revenues of $12 million in the quarter represented a 12.7% decline from the prior-year period. Cash Position Globus Medical exited the second quarter ...

  3. Bio-Rad (Bio) Q2 Earnings Beat Estimates, Margins Expand

    Zacks via Yahoo FinanceAug 02 13:15 PM

    Revenues in Detail Revenues in the quarter totaled $572.6 million, beating the Zacks Consensus Estimate by 1.7%. Revenues fell 0.6% from the year-ago quarter (up 2.7% at constant currency or ...

  4. Pacific Biosciences (PACB) Beats on Q2 Earnings & Revenues

    Zacks via Yahoo FinanceAug 09 12:54 PM

    Pacific Biosciences of California, Inc. PACB incurred second-quarter 2019 adjusted loss of 16 cents per share, narrower than the Zacks Consensus Estimate of a loss of 18 cents. The company had incurred a loss of 17 cents in the year-ago quarter.

  5. The Zacks Rank #4 (Sell) company posted revenues of $93.6 million, outpacing the Zacks Consensus Estimate of $88 million. The figure also surpassed the company's expectations. However, revenues dropped 2.6% year over year.

  6. p style="text-align:justify;">Intersect ENT Inc. XENT reported second-quarter 2019 loss per share of 36 cents, wider than the Zacks Consensus Estimate of a loss of 34 cents. The reported loss ...

  7. Here's Why You Should Add Stryker (SYK) to Your Portfolio

    Zacks via Yahoo FinanceAug 21 12:54 PM

    Factors to Boost Stryker Stryker delivered second-quarter 2019 adjusted earnings per share (EPS) of $1.98, beating the Zacks Consensus Estimate by 2.6%. The bottom line improved ...

  8. DENTSPLY SIRONA (XRAY) Q2 Earnings Beat, Revenues Fall Y/Y

    Zacks via Yahoo FinanceAug 02 12:34 PM

    Per management, internal sales growth was 3%.

  9. Adjusted EPS beat the Zacks Consensus Estimate by 1.2% on revenue growth across global Medical and Technology and Value-added Services businesses. p> On a reported basis, EPS from continuing ...

  10. Segmental Details Sales revenues amounted to $95.9 million in the quarter under review, up 4.2% on a year-over-year basis.